Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma

Original Article

M.W. Rohaan, T.H. Borch, J.H.v.d. Berg, Ö. Met, R. Kessels, M.H.G. Foppen, J.S. Granhøj, B. Nuijen, C. Nijenhuis, I. Jedema, M.v. Zon, S. Scheij, J.H. Beijnen, M. Hansen, C. Voermans, I.M. Noringriis, T.J. Monberg, R.B. Holmstroem, L.D. Wever, M.v. Dijk, L.G. Grijpink-Ongering, L.H. Valkenet, A.T. Acosta, M. Karger, J.S. Borgers, R.M.t. Ham, V.P. Retèl, W.H.v. Harten, F. Lalezari, H.v. Tinteren, A.A.v.d. Veldt, G.A. Hospers, M.A.S. Boer, K.P. Suijkerbuijk, M.J. Aarts, D. Piersma, A.J.v.d. Eertwegh, J.-W.B.d. Groot, G. Vreugdenhil, E. Kapiteijn, M.J. Boers-Sonderen, W.E. Fiets, F.W.v.d. Berkmortel, E. Ellebaek, L.R. Hölmich, A.C.v. Akkooi, W.J.v. Houdt, M.W. Wouters, J.V.v. Thienen, C.U. Blank, A. Meerveld-Eggink, S. Klobuch, S. Wilgenhof, T.N. Schumacher, M. Donia, I.M. Svane, and J.B. Haanen

N Engl J Med 2022;387:2113-2125

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit
  • 1.00 Participation
Course opens: 
12/07/2022
Course expires: 
12/08/2024

Available Credit

  • 1.00 AMA PRA Category 1 Credit
  • 1.00 Participation

Course closed

This course closed on Sunday, December 8, 2024 - 11:59pm.